<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335193">
  <stage>Registered</stage>
  <submitdate>2/03/2010</submitdate>
  <approvaldate>10/03/2010</approvaldate>
  <actrnumber>ACTRN12610000202066</actrnumber>
  <trial_identification>
    <studytitle>Assessing the risk of heart disease in women with polycystic ovary syndrome</studytitle>
    <scientifictitle>Assessment of cardiovascular risk in polycystic ovary syndrome - effects of therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Polycystic ovary syndrome</healthcondition>
    <healthcondition>Cardiovascular risk</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Metformin - oral tablet.
To be taken at dose 750mg, twice a day for a total duration of 12 weeks with 4 week washout period before moving onto the placebo (or vice versa)</interventions>
    <comparator>Sugar pill orally twice a day for a duration of 12 weeks with 4 week washout period before mevoing onto the metformin treatment (or vice versa)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Platelet nitric oxide reponsiveness
- 10 mls of venous blood will be obtained. Platelet aggregation in response to adenosine diphosphate (ADP 2.5uM) and its inhibition of aggregation by the exogenous nitric oxide donor, sodium nitroprusside (10uM) will be measured using platelet aggregometer</outcome>
      <timepoint>3months after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Homeostasis model assessment of insulin resistance (HOMAR-IR)</outcome>
      <timepoint>3 months from randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Endothelial function
- using applanation tonometry at baseline and in response to nitrolingual sublingually(25mcg) and salbulatamol inhaled (400mcg)</outcome>
      <timepoint>3 months from randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women with previously diagnosed polycystic ovary syndrome</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Already on metformin or oral contraceptives
On clopidogrel</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Performed by pharmacy - Allocation was concealed using numbered containers
The person recruiting patients for trial are blinded to the group that patient will be allocated</concealment>
    <sequence>1. Randomisation and packaging performed by Pharmacy Department
2. Numbered boxes</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/03/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Cardiology Unit</primarysponsorname>
    <primarysponsoraddress>The Queen Elizabeth Hospital
28 Woodville Road
Woodville South 
SA 5011</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Cardiology Unit</fundingname>
      <fundingaddress>The Queen Elizabeth Hospital
28 Woodville Road
Woodville South 
SA 5011</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Cardiology Unit</sponsorname>
      <sponsoraddress>The Queen Elizabeth Hospital
28 Woodville Road
Woodville South 
SA 5011</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Metformin is a commonly used medication in the management of polycystic ovary syndrome (PCOS). It appears to play an improtant role in the regulation of menstural cycles, fertility and improvement in insulin sensitivity in PCOS. We have recently shown in a small group of young PCOS women the evidence of marked abnormalities in both platelet and endothelial function (surrogate markers of increased cardiovascular risk) when compared to nromal controls. The primary aim is to assess if metformin improves/reverses these anomalies.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee</ethicname>
      <ethicaddress>Basil Hetzel Institute
Woodville Road
Woodville South
SA 5011</ethicaddress>
      <ethicapprovaldate>11/01/2010</ethicapprovaldate>
      <hrec>2008046</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor John Horowitz</name>
      <address>Cardiology Unit 
The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
SA 5011</address>
      <phone>+61882227539</phone>
      <fax>+61882226422</fax>
      <email>john.horowitz@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Alicia Chan</name>
      <address>Cardiology Unit 
The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
SA 5011</address>
      <phone>+61882227539</phone>
      <fax>+61882226422</fax>
      <email>wai.chan@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Alicia Chan</name>
      <address>Cardiology Unit 
The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
SA 5011</address>
      <phone>+61882227539</phone>
      <fax>+61882226422</fax>
      <email>wai.chan@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>